| Early childhood development coming of age: science through the life course MM Black, SP Walker, LCH Fernald, CT Andersen, AM DiGirolamo, C Lu, ... The lancet 389 (10064), 77-90, 2017 | 3129 | 2017 |
| Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial AV Balar, MD Galsky, JE Rosenberg, T Powles, DP Petrylak, J Bellmunt, ... The Lancet 389 (10064), 67-76, 2017 | 2274 | 2017 |
| Safety and efficacy of durvalumab (MEDI4736), an anti–programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer C Massard, MS Gordon, S Sharma, S Rafii, ZA Wainberg, J Luke, ... Journal of Clinical Oncology 34 (26), 3119-3125, 2016 | 935 | 2016 |
| An HNF4α-miRNA inflammatory feedback circuit regulates hepatocellular oncogenesis M Hatziapostolou, C Polytarchou, E Aggelidou, A Drakaki, GA Poultsides, ... Cell 147 (6), 1233-1247, 2011 | 564 | 2011 |
| Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial T Powles, T Csőszi, M Özgüroğlu, N Matsubara, L Géczi, SYS Cheng, ... The Lancet Oncology 22 (7), 931-945, 2021 | 554 | 2021 |
| Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma … T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ... The Lancet Oncology 21 (12), 1574-1588, 2020 | 465 | 2020 |
| Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial J Bellmunt, M Hussain, JE Gschwend, P Albers, S Oudard, D Castellano, ... The Lancet Oncology 22 (4), 525-537, 2021 | 348 | 2021 |
| Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer T Powles, BP Valderrama, S Gupta, J Bedke, E Kikuchi, ... New England Journal of Medicine 390 (10), 875-888, 2024 | 337 | 2024 |
| Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008 N Donin, C Filson, A Drakaki, HJ Tan, A Castillo, L Kwan, M Litwin, ... Cancer 122 (19), 3075-3086, 2016 | 325 | 2016 |
| Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised … DP Petrylak, R De Wit, KN Chi, A Drakaki, CN Sternberg, H Nishiyama, ... The Lancet 390 (10109), 2266-2277, 2017 | 256 | 2017 |
| MiR-27b targets PPARγ to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells JJ Lee, A Drakaki, D Iliopoulos, K Struhl Oncogene 31 (33), 3818-3825, 2012 | 185 | 2012 |
| Immunotherapy for the treatment of urothelial carcinoma NM Donin, AT Lenis, S Holden, A Drakaki, A Pantuck, A Belldegrun, ... Journal of Urology 197 (1), 14-22, 2017 | 148 | 2017 |
| MicroRNA gene networks in oncogenesis A Drakaki, D Iliopoulos Current genomics 10 (1), 35-41, 2009 | 124 | 2009 |
| Modulating BET bromodomain inhibitor ZEN‐3694 and enzalutamide combination dosing in a metastatic prostate cancer patient using CURATE. AI, an artificial intelligence platform AJ Pantuck, DK Lee, T Kee, P Wang, S Lakhotia, MH Silverman, C Mathis, ... Advanced Therapeutics 1 (6), 1800104, 2018 | 120 | 2018 |
| Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial A Naing, DJ Wong, JR Infante, WM Korn, R Aljumaily, KP Papadopoulos, ... The Lancet Oncology 20 (11), 1544-1555, 2019 | 113 | 2019 |
| Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA N Agarwal, SK Pal, AW Hahn, RH Nussenzveig, GR Pond, SV Gupta, ... Cancer 124 (10), 2115-2124, 2018 | 102 | 2018 |
| Impact of performance status on treatment outcomes: a real‐world study of advanced urothelial cancer treated with immune checkpoint inhibitors AR Khaki, A Li, LN Diamantopoulos, MA Bilen, V Santos, J Esther, ... Cancer 126 (6), 1208-1216, 2020 | 87 | 2020 |
| Epigenetic regulation of hTERT promoter in hepatocellular carcinomas D Iliopoulos, M Satra, A Drakaki, GA Poultsides, A Tsezou International journal of oncology 34 (2), 391-399, 2009 | 71 | 2009 |
| Functional microRNA high throughput screening reveals miR-9 as a central regulator of liver oncogenesis by affecting the PPARA-CDH1 pathway A Drakaki, M Hatziapostolou, C Polytarchou, C Vorvis, GA Poultsides, ... BMC cancer 15, 1-11, 2015 | 68 | 2015 |
| Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art C Lebacle, A Pooli, T Bessede, J Irani, AJ Pantuck, A Drakaki World journal of urology 37, 115-123, 2019 | 57 | 2019 |
